Tuesday, September 27, 2016 1:47:10 PM
1. Their Phase 3 trial didnt show efficacy
2. They have 2 others in Phase 2
3. They have 35 MILLION in cash!
4. They are paying a 10 million payment toward debt, which will leave them only 3.2 million in debt.
5. They will have betwee 20-25 MILLION in CASH on hand after that initial payment.
....looks like they're doing ok to me. On cash value ALONE, this is undervalued.
The stock is also waaay oversold.
Let's stick to honest statements. Good day.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM